

03-25-03

1652

EXPRESS MAIL CERTIFICATE

Date 3/24/03 Label No. EV294038935US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Rost Office to Addressee" service.

J. Staudine J. Staudine
Name (Print) Signature

PLEASE CHARGE ANY DEFICIENCY OR CREDIT ANY EXCESS
IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT
ACCOUNT NO. 04-0100



Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 4305/0J425

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Henrik CLAUSEN and Tilo SCHWIENTEK

RECEIVED

MAR 27 2003

Serial No.: 09/874,390

TECH CENTER 1600/2900

Confirmation No.: 5094

Art Unit: 1652

Filed: June 4, 2001

Examiner: Rao, M. N.

For: UDP-N-Acetylglucosamine:Galactose- β 1,3-N-Acetylgalactosamine et al.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

BEST AVAILABLE COPY

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does

Serial No. 09/874,390

Docket No. 4305/0J425

not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Since some of the documents were known to the applicant for more than three months before the filing of this Information Disclosure Statement, the statutory fee of \$180.00 under 37 C.F.R. 1.17(p) is enclosed. The Commissioner is authorized to charge any additional fees required in connection with this Petition or to credit any overpayment to Deposit Account No. 04-0100.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

BEST AVAILABLE COPY

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: March 24, 2003


Heather M. Ettinger
Registration No. 51,658
Attorney for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700

BEST AVAILABLE COPY



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 1 OF 2
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

RECEIVED

MAR 27 2003

DOCKET NO.: 4305/OJ425
APPLICANT: Henrik CLAUSEN
Tilo SCHWIENTEKSERIAL NO: 09/874,390
FILING DATE: June 4, 2001
CONFIRMATION NO: 5094

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------	----------------------------	-------------	-------------	--------------	-----------------	--------------------

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>TRANSLATION SUBCLASS</u>	<u>YES</u>	<u>NO</u>
	1. WO 95/07020	Mar. 16, 1995	WO	A01N	37/18		
	2. EPO 0 590 747 A2	Apr. 6, 1994	EPO	C12N	15/54		

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)***EXAMINER
INITIALS

3. Almeida et al., Glycoconjugate J. 1997, 14:S44
4. Asano, M. et al. EMBO J. 16:1850-1857, 1997
5. Axford, J.S. et al., Autoimmunity 17:157-163, 1994
6. Breathnach, R. et al., Ann. Rev. Biochem. 50:349-83, 1981
7. Brew, K. et al., Biochemistry 59:491-97, 1968
8. D'Agostaro, G. et al., Eur. J. Biochem. 183:211-217, 1989
9. Devereux et al., Nucleic Acids Research, 1984; 12(1)
10. Fujita-Yamaguchi, Y. et al., J. Biol. Chem. 256(6):2701-2706, March 25, 1981
11. Furukawa, K. et al., Inter. Immunology 2(1):105-112, 1990
12. Gentzsch, M. and Tanner, W. (1996) EMBO J., 15:5752-5759
13. Hollis, G.F. et al., Biophys Res Comm. 162:1069-1075, 1989
14. Johnston, D. et al. (1998) J. Biol. Chem. 273(4):1888-1895
15. Keusch, J., et al., Glycobiology 5:365-700, 1995
16. Kobata, A. Eur J. Biochem. 209:483-501, 1992
17. Kozak, M., Ann Rev Cell Biol. 8:197-225, 1992
18. Lo et al., Glycobiology (1998), 8:517-526
19. Lu, Q., et al., Develop Biol. 18:257-267, 1997
20. Malissard, M., et al., (1996) Eur J. Biochem. 239:340-348
21. Masri, K.A., et al., (1988) Biochem Res Comm. 157:657-663



FORM PTO-

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 2 OF 2
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

RECEIVED

MAR 27 2003

DOCKET NO.: 4305/OJ425
APPLICANT: Henrik CLAUSEN
Tilo SCHWIENTEKSERIAL NO: 09/874,390
FILING DATE: June 4, 2001
CONFIRMATION NO: 5094

TECH CENTER 1600/400

22. Matteucci et al., J. Am. Chem. Soc., 1981; 103:3185-3191
23. Mengle-Gaw, L., et al. (1985) Biophys Res Comm. 176:1269-1276
24. Moscarello M.A., et al. (1991) Biochim Biophys Acta. 831:192-200
25. Nakazawa, K. et al. (1988) J. Biochem. 104:165-168
26. Nakazawa K. et al. (1991) Eur J. Biochem. 196:363-368
27. Narimatsu, H. et al. (1986) Proc Natl Acad Sci USA. 83:4720-4724
28. Parquet, M.R. et al., (1984) Biochem J. 218:745-751
29. Perillo et al., J. Mol. Med., 1998; 76:402-412
30. Perillo et al., Nature, 1995; 378:736-739
31. Piller et al., Journ. of Biol. Chem., 1988; 263(29):15146-15150
32. Powell, J.T. and Brew, K. (1974) Eur J Biochem. 48:217-228
33. Sato, T. et al., (1988) Biochem & Biophysical Res. Comm. 244(3):637-641
34. Shaper, J.H. et al. (1995) Glycoconjugate J. 12:477
35. Shaper, N.L. et al. (1986) Proc Nat'l Acad Sci USA. 83:1573-1577
36. Shaper, N.L. et al. (1988) J. Biol. Chem. 263:10420-10428
37. Shaper, N.L. et al. (1997) J. Biol. Chem. 272:31389-31399
38. Sheares, B.T. and Carlson, D. (1984) J. Biol. Chem. 259:8045-8047
39. Shur, B.D. (1982) J. Biol. Chem. 257:6871-6878
40. Williams et al., Journ. of Biol. Chem., 1980; 255(23):11247-11252
41. Wilson, I.B. et al. (1993) J. Rheumatol. 20:1282-1287
42. Yang et al., Glycobiology, 1994; 4(6):873-884
43. Yeh et al., Journ. of Biol. Chem., 1999; 274(5):3215-3221
44. Yoo et al., Journ. of Biol. Chem., 1989; 264(29):17078-17083

CO-PENDING APPLICATIONSU.S. Serial No. 60/425,204
U.S. Serial No. 10/292,896
U.S. Serial No. 09/118,464
U.S. Serial No. 10/132,652
U.S. Serial No. 09/645,192
U.S. Serial No. 10/084,406

EXAMINER: _____

DATE CONSIDERED: _____

***EXAMINER:**

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY